
The European Commission has greenlighted Novo Nordisk’s Rybelsus (oral semaglutide) as an adjunct to diet and exercise to improve glycaemic …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

